Li, Ding & Li (2016) hypothesized a diagnostic use of COL1A1 to screen for early GC. They also considered COL1A1 and COL1A2 as predictors of poor clinical outcomes in GC patients. In contrast, Sun et al. (2014) showed that THBS2 expression was significantly lower in GC tissues compared to normal tissues, and that patients with higher levels of THBS2 had better prognosis. However, Zhuo et al. (2016) found higher expression of THBS2 and COL1A2 in tumor tissues and better prognosis in patients with lower THBS2 expression. This evidence concerns the gene COL1A1 and neoplasm.